

Minutes
Drug Allergy GDG 2
Location: National Clinical Guidelines Centre
5th Floor, 180 Great Portland Street, London, W1W 5QZ
January 25th 2013, 1000 – 1600

Attendees

GDG

Shuaib Nasser
Alice Osborne
Andrew Williams
David Cousins
James Larcombe
Mandy East
Mike Arden-Jones
Nicola Mundy
Paul Whitaker
Pamela Ewan
George Du Toit

NICE

Caroline Keir

NCGC

Carlos Sharpin
Gill Ritchie
Grace Marsden
Kate Kelley
Kathy De Mott
Lee Yee Chong
Margaret Constanti
Tamara Diaz
Vicki Pollit

GDG Apologies:

None

1. Welcome, introductions and apologies

The Chair welcomed all to GDG meeting two for the Drug Allergy guideline and asked the group to introduce themselves. The group was introduced to Caroline Keir, the newly assigned NICE guidelines commissioning manager, Gill Ritchie who replaces Kate Kelley as Guideline lead and an NCGC meeting observer, Grace Marsden, NCGC health economist.

There were no formal apologies from group members.

2. Declarations of interest

The chair invited group members to declare interests related to the days agenda. There were no new declarations of interest from the group.

3. GDG 2 meeting agenda

The chair provided an overview of the agenda, highlighting the day's objectives and goals.

4. Drug Allergy Scope

5. Guideline lead, GR, provided an update on the finalisation of the scope for the guideline. The Guidelines Commissioning Manager CK and the chair led discussions and provided responses to the GDG related to proposed edits to the scope.

6. Searching for and reviewing evidence

A presentation was delivered to the group on review protocol details. Highlighting the elements of review protocols and the information the technical team hoped to obtain from the day's planned group activities.

7. Survey Results

The list of clinical review questions, designed to cover the scope of the guideline, was presented to the group. This final list had been compiled following a survey of GDG members.

8. Finalising review protocols

Three pre-assigned sub groups were used to refine review protocols for the following clinical areas:

- 8.1. Serum IgE
- 8.2. Serum Tryptase
- 8.3. Signs and Symptoms
- 8.4. Information

At the end of the subgroup break out session, members summarised discussion points and suggestions for the full group and technical team.

9. Confirmation of Minutes of GDG 1

There being no suggested edits, the GDG confirmed the accuracy of the circulated minutes.

10. Health Economics

MC, the assigned guideline health economist delivered a presentation entitled, 'Priorities for modelling'.

The GDG was asked to identify 4 areas which they consider a priority for economic analysis for the guideline and to share their thoughts on feasibility, make suggestions on possible data sources and identify the costs/benefits of each suggested area. A draft drug allergy algorithm was circulated for the group's further consideration.

11. Introduction to Claromentis

The Project Manager, TD provided a brief demonstration and introduction to the NCGC's online document management system.

12. Summary of next steps and close of business:

There being no further business the meeting ended at 4:00 p.m. the dates of the next two meetings of the drug allergy guideline development group was announce, these will take place on 2nd and 3rd May, 2013 at the NCGC's offices.